The largest database of trusted experimental protocols
> Disorders > Anatomical Abnormality > Nasal Polyps

Nasal Polyps

Nasal Polyps are non-cancerous growths that develop on the lining of the nasal passages or sinuses.
These soft, painless swellings can block airflow and drainage, leading to symptoms like nasal congestion, runny nose, and decreased sense of smell.
Nasal Polyps are often associated with chronic sinus infections, allergies, and asthma.
Effective treatment options include nasal sprays, oral medications, and in some cases, surgery to remove the polyps.
Understanding the latest research on Nasal Polyps can help healthcare providers deliver better care and improve patient outcomes.
PubCompare.ai's AI-driven platform can assist researchers in optimizing their Nasal Polyps studies by locating the best protocols from literature, pre-prints, and patens, enhancing reproducibility and acuracy.

Most cited protocols related to «Nasal Polyps»

This multicenter retrospective study was implemented to examine the factors related to recurrence or refractoriness of CRS in the Japanese population from 2011 to 2012. ‘Recurrent’ CRS was defined as CRS that presented recurring nasal polyps or sinusitis (nasal symptoms) after ESS. ‘Refractory’ CRS was defined as recurrent CRS that was not cured by any medical treatment after ESS. This study was conducted in 15 institutions of Japan and related facilities participating in the grants‐in‐aid program (Ministry of Health, Labour and Welfare Grant; Japan Epidemiological Survey of Refractory Eosinophilic Chronic Rhinosinusitis [JESREC] Study). The study was approved by the ethics committee of each institution participating in the JESREC Study.
We assessed patients with CRS (including CRSwNP and CRSsNP) treated with ESS from January 2007 to December 2009 in the 15 institutions. The diagnosis of sinus disease was based on patient history, clinical examination, nasal endoscopy, and computed tomography (CT) of the sinuses, according to the guidelines of the European Position Paper on Rhinosinusitis and Nasal Polyps 1. Our study excluded patients treated with systemic or topical corticosteroids before surgery, patients whose information on systemic or topical corticosteroids was unknown, patients who were followed up for <28 days after surgery, patients whose white blood cell counts were 10 000/μl or more, as well as patients from which there was no pathological specimen.
Preoperative demographic and medical history including sex, age, age of onset, reaction to drugs, history of smoking, complications, and drug allergies were obtained from each patient. Rhinology specialists assessed all participants on seven symptoms and signs before surgery: nasal polyps, viscous rhinorrhea, postnasal drip, facial pain, hyposmia, anosmia, and closure of the olfactory cleft. Blood samples were taken to perform complete blood counts and measure 10 types of antigen‐specific IgE. CT findings were graded according to the Lund–MacKay method 13. Recurrence of CRS was defined as the presence of nasal polyps or nasal symptoms in nasal endoscopy.
Publication 2015
Adrenal Cortex Hormones Antigens BLOOD Complete Blood Count Diagnosis Drug Allergy Drug Reaction, Adverse Endoscopy, Gastrointestinal Eosinophil Europeans Facial Pain Hyposmia Institutional Ethics Committees Japanese Leukocyte Count Nasal Polyps Nose Ocular Refraction Operative Surgical Procedures Patients Physical Examination Recurrence Rhinorrhea Sense of Smell Sinus Disease, Paranasal Sinuses, Nasal Sinusitis Specialists Viscosity X-Ray Computed Tomography

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2009
Adult Antibiotics Aspirin Asthma Clinical Reasoning Dental Caries Diagnosis Disabled Persons Endoscopy, Gastrointestinal Ethics Committees, Research Ethmoid Bone Ethnicity Gender Households Hypersensitivity Mucous Membrane Nasal Polyps Operative Surgical Procedures Patients Pharmaceutical Preparations Physicians Radionuclide Imaging Sinuses, Nasal Sinusitis Steroids Surgical Endoscopy Therapeutics Woman X-Ray Computed Tomography
Adult patients (aged ≥ 18 years) with a current diagnosis of medically refractory CRS were prospectively enrolled into an ongoing North American, multi-institutional, observational, treatment outcomes investigation between April, 2011 and January, 2014. Preliminary findings from this cohort have been described elsewhere.14 (link),16 (link) Diagnosis of CRS was defined by the 2007 Adult Sinusitis Guideline endorsed by the American Academy of Otolaryngology-Head and Neck Surgery.17 (link) All patients had been previously treated with an oral, broad spectrum, or culture directed antibiotic (≥2 weeks duration) and either topical nasal corticosteroid sprays (≥3 week duration) or a 5-day trial of systemic steroid therapy. Enrollment sites consisted of four academic, tertiary care rhinology practices, including Oregon Health & Science University (OHSU, Portland, OR, USA), the Medical Univeristy of South Carolina (Charleston, SC, USA), Stanford University (Palo Alto, CA, USA), and the University of Calgary (Calgary, Alberta, Canada). The Institutional Review Board at each enrollment location approved all investigational protocols and informed consent processes.
During the initial clinical / enrollment visit, all study subjects completed a medical history, head and neck clinical examinations, sinonasal endoscopy, and computed tomography (CT) imaging of the sinuses as part of the standard of care. Information was collected from patients and the medical record including age, gender, race, ethnicity, nasal polyposis, history of prior sinus surgery, asthma, acetylsalicylic acid (ASA) intolerance, current tobacco use (packs/day), alcohol consumption (grams/week), depression, allergies (reported by patient history or confirmed skin prick or radioallergosorbent testing), ciliary dysfunction / cystic fibrosis, recurrent acute rhinosinusitis (RARS), obstructive sleep apnea (OSA), and asthma / sinusitis related steroid dependency. Trained project coordinators at each enrollment site assisted with both informed consent and all study data collection.
Publication 2014
Adrenal Cortex Hormones Adult Antibiotics Aspirin Asthma Conditioning, Psychology Cystic Fibrosis Diagnosis Endoscopy Ethics Committees, Research Ethnicity Eyelashes Gender Head Hypersensitivity Nasal Polyps Nasal Sprays Neck North American People Operative Surgical Procedures Otorhinolaryngologic Surgical Procedures Patients Physical Examination Sinuses, Nasal Sinusitis Skin Sleep Apnea, Obstructive Steroids Therapeutics X-Ray Computed Tomography

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2017
Donors Epithelial Cells Nasal Polyps Tissues
Selection bias was assessed by comparing respondents and non-respondents to the CRISP Questionnaire on EHR data that included age, race/ethnicity, sex, history of receiving Medical Assistance (surrogate for socioeconomic status (SES))[14 ] the Charlson co-morbidity index [15 ] and EHR sampling strata. Next, prevalence of CRS and CRS symptoms was estimated using SAS Proc SURVEYFREQ [16 ] to account for sampling fraction and adjust for differential selection using previously published probabilities and participation weights, a standard methodology for referring back to the source population [17 –18 ].
We conducted unadjusted and adjusted analyses to identify sociodemographic, smoking, and health factors associated with CRS and CRS symptom subgroups. Sociodemographic factors evaluated included sex, race/ethnicity, age, and lifetime Medical Assistance status. Health outcomes included self-reported physician diagnosis of CRS, nasal polyps, asthma, aspirin-intolerant asthma, and hay fever, as well as migraine and fatigue determined by previously validated scales [19 (link)]. In unadjusted analysis we used the chi-square test to compare these factors between current CRS and never CRS and across CRS symptom subgroups. In adjusted analysis, we evaluated sociodemographic and health factors separately. For sociodemographic factors we created separate logistic regression models for current CRS (vs. never CRS) and each of the CRS symptom subgroups (vs. never CRS). Each model included sex (male, female); race/ethnicity (white, other), age (linear and quadratic terms to allow for non-linearity), smoking status (current, former, never), and Medical Assistance status (yes, no). To identify health outcomes associated with CRS, we used separate logistic models for each health outcome. Each model included a categorical variable for CRS status (never (reference), OBS/DIS, PP, SL, PPSL) as the primary independent variable and the sociodemographic and smoking variables as covariates.
All modeling was done using SAS Proc SURVEYLOGISTIC procedure, which accounted for the complex sampling design, and utilized sampling and participation weights [17 –18 ]. Weighted analysis balances bias with precision in association estimates; bias is reduced with weighted analysis but precision is also reduced (larger standard errors leading to larger confidence intervals) [17 –18 ]. One of the sampling weights was an order of magnitude larger than any other (weight = 150), because of the under-sampling of white subjects in the “No sinus codes” group. Using this weight severely inflated standard errors, a known consequence of large sampling weights [17 –19 (link)], so it was truncated to the next largest value (weight = 32), a standard method for dealing with large weights.
Publication 2016
Aspirin Asthma Diagnosis Ethnicity Fatigue Fever, Hay Males Migraine Disorders Nasal Polyps Physicians Sinuses, Nasal Woman

Most recents protocols related to «Nasal Polyps»

The experts comprised 16 practicing physicians from Belgium, Denmark, Finland, The Netherlands, Norway, and Sweden. Each was selected for their experience in managing patients with asthma and/or CRS. Also considered was their involvement in scientific meetings, guidelines, and education, and publications records. Selection ensured a variety of care models, and equal numbers of pulmonologists and ENT physicians/rhinologists—including those also specialized in allergology—were represented.
The expert group was led by a Steering Committee of eight individuals with at least one member from each country, and co-chaired by one pulmonologist and one ENT physician. The Steering Committee guided the project's scope and provided clinical leadership.
To ensure the suggestions arising from the experts’ discussions were relevant to patients’ and primary care concerns, the all-expert meeting was joined by a practicing GP from Norway, and a patient from Finland with severe asthma and CRS.
For the purposes of this initiative, CRSwNP was defined as per the European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS) 2020 guidelines (44 (link)).
Full text: Click here
Publication 2023
Asthma Erythropoietin Europeans Nasal Polyps Otolaryngologist Patients Physicians Primary Health Care Pulmonologists
We conducted an observational, prospective, monocentric study. Patients attended our center for two visits, at baseline (T0) and after one year from the first visit (T1). All participants started biologic therapy with benralizumab immediately after T0.
For every patient detailed clinical data were recorded such as general characteristics, comorbidities, allergic status, smoking habit, inhaled therapy, and number of previous sinus surgery.
At both T0 and T1, all subjects performed the following investigations: blood eosinophil count, total serum Ig-E, respiratory function assessment with pre-post bronchodilator spirometry, exhaled nitric oxide (FeNO) test, asthma symptoms assessment with Asthma Control Test (ACT), OCS therapy with daily dosage, number of previous year exacerbations, ENT examination with nasal endoscopy for obtaining Nasal Polyp Score (NPS), nasal cytologic sampling, CRswNP symptoms assessment with Sino-Nasal Outcome Test 22 (SNOT 22). In addition, the need for sinus surgery was assessed for each patient at T1.
Publication 2023
Asthma benralizumab Bronchodilator Agents Cytological Techniques Endoscopy Eosinophil Nasal Polyps Nose Operative Surgical Procedures Oxide, Nitric Patients Respiratory Physiology Serum Sinuses, Nasal Spirometry Symptom Assessment Therapeutics Therapies, Biological
Patients were recruited to the study in the period from June to October 2020 based on the diagnostic criteria of CRS including medical history, physical examination, nasal endoscopy, and computed tomography (CT) scan of the sinuses. Nasal polyp tissue specimens were obtained laterally to the concha nasalis media during endonasal sinus surgery from CRSwNP patients (n = 15) after 14 days of 1,8-Cineol administration as well as from CRSwNP patients (n = 15) without prior 1,8-Cineol administration. Before surgery, all patients had been free of steroid medication for at least four weeks. Fresh tissue samples were flash frozen in liquid nitrogen immediately after resection and stored at − 80 °C.
1,8-Cineol (CNL-1976) was used in terms of the clinically approved drug Soledum® Kapseln forte (capsules) (Cassella-med GmbH & Co. KG, Cologne, Germany). For therapeutic use patients have been prescribed Soledum capsules (3 × 200 mg/day) over 14 days. We analyzed 30 CRSwNP patients (22 men, 8 women) with a mean age of 50.9 years.
Tissue homogenates of nasal polyps from 30 CRSwNP patients were prepared in glass vials using the Omni Tissue Master Homogenizer (Perkin Elmer GmbH, Hamburg, Germany) in ice cold phosphate buffered saline (PBS). The protein concentrations of the samples were determined using Bradford's assay (BioRad Laboratories GmbH, Munich, Germany) following the manufacturer's instructions. Samples were stored at − 80 °C.
Full text: Click here
Publication 2023
Biological Assay Capsule Common Cold Diagnosis Endoscopy Eucalyptol Freezing Nasal Polyps Nitrogen Nose Operative Surgical Procedures Patients Pharmaceutical Preparations Phosphates Physical Examination Proteins Radionuclide Imaging Saline Solution Sinuses, Nasal Soledum Steroids Therapeutic Uses Tissues Turbinates Woman X-Ray Computed Tomography
A sensitive gas chromatography-mass spectrometry (GC–MS) method has been developed and validated for the detection and quantification of 1,8-Cineol in tissue samples of nasal polyps from CRSwNP patients.
The analytes were chromatographically separated on a fused silica column with 95% dimethyl and 5% diphenyl polysiloxane (Rtx-5 Amine; 30 m, 0,25 mm ID, 0,25 µm film-thickness; Restek Corporation, Bellefonte, PA, USA) using a 6890N with MSD 5973 Network gas chromatography mass spectrometry system (Agilent Technologies Inc., Santa Clara, CA, USA). The temperature program used for chromatographic separation is described in Table 1. Helium (5.0, Messer GmbH, Bad Soden am Taunus, Germany) at a constant flow of 1.5 mL/min was used as a carrier gas. Electron ionization (EI) at 70 eV was used at a source temperature of 230 °C. Mass spectrometric determination was performed in selective ion monitoring (SIM) mode, analyzing the masses m/z 154 (used for quantification) and m/z 108 as a qualifier for 1,8-Cineol. Quantifier and qualifier mass transitions for 1,4-Cineol were m/z 111 and m/z 154, respectively. MS quadrupole temperature was 150 °C. A solvent delay of 4 min was used with following acquisition for 10 min.

Temperature program of the gas chromatograph.

Ramp noRate [°C/min]End temperature [°C]Time [min]
Start0502
1201300
2302500
Post-run02902
MassHunter GC/MS Acquisition (B.07.06.2704, Agilent Technologies. Inc. Santa Clara, CA, USA) and MassHunter Workstation Quantitative Analysis (B.09.00) were employed for data acquisition and evaluation.
Full text: Click here
Publication 2023
Amines Chromatography diphenyl Electrons Eucalyptol Gas Chromatography Gas Chromatography-Mass Spectrometry Helium Mass Spectrometry Nasal Polyps Patients Silicon Dioxide Siloxanes Solvents Tissues
Data collection was carried out by consulting patients’ medical records, during follow-up consultations, or through teleconsultation due to the current SARS-CoV-2 pandemic. We collected information regarding sex, age, comorbidities [asthma, aspirin-exacerbated respiratory disease (AERD), diabetes, cardiovascular diseases, chronic obstructive pulmonary disease (COPD), etc.], treatments and doses of corticoid therapies, history of nasal surgery with type and date and eosinophil levels. We also analysed the nasal polyp score (NPS) (range: 0/4 to 4/4 for each side) preoperatively and one month after surgery.
Publication 2023
Adrenal Cortex Hormones Aspirin Asthma Cardiovascular Diseases Chronic Obstructive Airway Disease Diabetes Mellitus Eosinophil Nasal Polyps Operative Surgical Procedures Outpatients Pandemics Respiration Disorders SARS-CoV-2 Surgical Procedure, Nasal Teleconsultation

Top products related to «Nasal Polyps»

Sourced in United States, China, United Kingdom, Germany, Australia, Japan, Canada, Italy, France, Switzerland, New Zealand, Brazil, Belgium, India, Spain, Israel, Austria, Poland, Ireland, Sweden, Macao, Netherlands, Denmark, Cameroon, Singapore, Portugal, Argentina, Holy See (Vatican City State), Morocco, Uruguay, Mexico, Thailand, Sao Tome and Principe, Hungary, Panama, Hong Kong, Norway, United Arab Emirates, Czechia, Russian Federation, Chile, Moldova, Republic of, Gabon, Palestine, State of, Saudi Arabia, Senegal
Fetal Bovine Serum (FBS) is a cell culture supplement derived from the blood of bovine fetuses. FBS provides a source of proteins, growth factors, and other components that support the growth and maintenance of various cell types in in vitro cell culture applications.
Sourced in United States, United Kingdom, Germany, China, France, Canada, Japan, Australia, Switzerland, Italy, Israel, Belgium, Austria, Spain, Brazil, Netherlands, Gabon, Denmark, Poland, Ireland, New Zealand, Sweden, Argentina, India, Macao, Uruguay, Portugal, Holy See (Vatican City State), Czechia, Singapore, Panama, Thailand, Moldova, Republic of, Finland, Morocco
Penicillin is a type of antibiotic used in laboratory settings. It is a broad-spectrum antimicrobial agent effective against a variety of bacteria. Penicillin functions by disrupting the bacterial cell wall, leading to cell death.
Sourced in United States, United Kingdom, Germany, China, France, Canada, Australia, Japan, Switzerland, Italy, Belgium, Israel, Austria, Spain, Netherlands, Poland, Brazil, Denmark, Argentina, Sweden, New Zealand, Ireland, India, Gabon, Macao, Portugal, Czechia, Singapore, Norway, Thailand, Uruguay, Moldova, Republic of, Finland, Panama
Streptomycin is a broad-spectrum antibiotic used in laboratory settings. It functions as a protein synthesis inhibitor, targeting the 30S subunit of bacterial ribosomes, which plays a crucial role in the translation of genetic information into proteins. Streptomycin is commonly used in microbiological research and applications that require selective inhibition of bacterial growth.
Sourced in United States, Germany, Switzerland, United Kingdom, Italy, Japan, Macao, Canada, Sao Tome and Principe, China, France, Australia, Spain, Belgium, Netherlands, Israel, Sweden, India
DNase I is a laboratory enzyme that functions to degrade DNA molecules. It catalyzes the hydrolytic cleavage of phosphodiester linkages in the DNA backbone, effectively breaking down DNA strands.
Sourced in Germany, United States, United Kingdom, Netherlands, Spain, Japan, Canada, France, China, Australia, Italy, Switzerland, Sweden, Belgium, Denmark, India, Jamaica, Singapore, Poland, Lithuania, Brazil, New Zealand, Austria, Hong Kong, Portugal, Romania, Cameroon, Norway
The RNeasy Mini Kit is a laboratory equipment designed for the purification of total RNA from a variety of sample types, including animal cells, tissues, and other biological materials. The kit utilizes a silica-based membrane technology to selectively bind and isolate RNA molecules, allowing for efficient extraction and recovery of high-quality RNA.
Sourced in United States
The BA-2000 is a laboratory instrument designed for the analysis of biological samples. It provides accurate and reliable measurements through its core function of spectrophotometric detection.
Sourced in United States, Germany, United Kingdom, Lithuania, Canada, France, Japan, Israel, Australia, Spain, Switzerland, Sweden
RNAlater solution is a nucleic acid stabilization reagent that immediately stabilizes and protects RNA in fresh tissue samples. It preserves the RNA in tissues and cells, preventing degradation and allowing for reliable downstream analysis.
Sourced in United States
Collagen-coated flasks are a type of cell culture vessel designed to provide a suitable surface for the attachment and growth of cells that require a collagen-rich extracellular matrix. The collagen coating helps to mimic the natural cell environment, promoting cell adhesion, proliferation, and differentiation.
Sourced in United States, United Kingdom, Germany, Japan, Lithuania, Italy, Australia, Canada, Denmark, China, New Zealand, Spain, Belgium, France, Sweden, Switzerland, Brazil, Austria, Ireland, India, Netherlands, Portugal, Jamaica
RNAlater is a RNA stabilization solution developed by Thermo Fisher Scientific. It is designed to protect RNA from degradation during sample collection, storage, and transportation. RNAlater stabilizes the RNA in tissues and cells, allowing for efficient RNA extraction and analysis.
Sourced in Switzerland, United States, Belgium, United Kingdom
Dulbecco's Modified Eagle Medium (DMEM) is a cell culture medium formulation that provides nutrients and growth factors necessary to support the in vitro cultivation of various cell types. It is a widely used and versatile medium designed to maintain the optimal growth and proliferation of cells in laboratory settings.

More about "Nasal Polyps"

Nasal polyps, also known as rhinopolyps or sinus polyps, are non-cancerous growths that develop on the lining of the nasal passages or paranasal sinuses.
These soft, painless swellings can obstruct airflow and drainage, leading to symptoms such as nasal congestion, runny nose, and diminished sense of smell.
Nasal polyps are often associated with chronic sinus infections (rhinosinusitis), allergies (e.g., allergic rhinitis), and respiratory conditions like asthma.
Effective treatment options for nasal polyps include the use of topical nasal sprays (e.g., corticosteroids), oral medications (e.g., antihistamines, decongestants, leukotriene inhibitors), and in some cases, surgical intervention to remove the polyps (polypectomy).
Understanding the latest research on nasal polyps, including studies involving Penicillin, Streptomycin, DNase I, RNeasy Mini Kit, BA-2000, RNAlater solution, Collagen-coated flasks, and RNAlater, can help healthcare providers deliver more effective care and improve patient outcomes.
PubCompare.ai's AI-driven platform can assist researchers in optimizing their nasal polyps studies by locating the best protocols from literature, pre-prints, and patents, enhancing reproducibility and accuracy.
By seamlessly comparing different approaches and products, researchers can identify the most effective strategies for managing and treating nasal polyps, ultimately contributing to advancements in this field of study.